What Is Retatrutide? (LY3437943 Explained)

The triple-agonist mechanism

Retatrutide is often described as a triple hormone-receptor agonist. That label refers to one molecule designed to activate three signaling pathways. The combination is intended to influence appetite, glucose-dependent insulin secretion, nutrient handling and energy metabolism. The clinical effect of the combined molecule—not any single receptor in isolation—is what current trials are evaluating.

The GLP-1 component is associated with appetite regulation, delayed gastric emptying and glucose-dependent insulin secretion. GIP receptor activity also contributes to glucose-dependent insulin release and may affect appetite and fat-tissue biology. Glucagon receptor activity is the distinguishing third element; experimental research links it with hepatic energy metabolism and expenditure, while also making careful safety evaluation important.

• GLP-1 receptor: appetite, gastric emptying and glucose-dependent insulin secretion.
• GIP receptor: insulinotropic signaling and broader nutrient regulation.
• Glucagon receptor: hepatic energy metabolism and energy-expenditure signaling.

Development history and current status

Early clinical studies established dose-ranging, tolerability and proof-of-concept findings. The 2023 Phase 2 obesity trial then reported dose-dependent weight change over 48 weeks, with gastrointestinal adverse events the most common category. A separate Phase 2 study examined glycemic and weight outcomes in adults with type 2 diabetes.

By 2026, multiple Phase 3 studies had progressed or completed. Lilly announced topline results from TRIUMPH-1 and TRANSCEND-T2D-1, while other studies—including a direct comparison with tirzepatide—continued. These announcements do not equal regulatory approval. Retatrutide remains investigational unless and until regulators review a formal application and grant an approval for a defined indication.

What retatrutide is being studied for

The clinical program spans obesity or overweight with weight-related complications, type 2 diabetes, cardiovascular and kidney outcomes, obstructive sleep apnea, knee osteoarthritis, and metabolic liver disease. Each study has its own population, endpoints and duration, so a result in one setting cannot automatically be generalized to another.

How it differs from earlier incretin medicines

Semaglutide activates the GLP-1 receptor. Tirzepatide activates GIP and GLP-1 receptors. Retatrutide adds glucagon receptor activity to GIP and GLP-1 activity. This is a mechanistic progression, not proof that one medicine is best for every person. Cross-trial percentages are influenced by study design, participant characteristics and estimand.

A Phase 3 head-to-head study of retatrutide and tirzepatide is designed to provide a more direct comparison. Until those results are available and reviewed, conclusions based only on separate trials should remain cautious.

Regulatory status in 2026

Retatrutide is not an FDA-approved medicine and has no approved prescribing information, commercial product, standard dose or approved price. Phase 3 completion and company-reported results are development milestones; they are not substitutes for a regulatory decision.